GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Return-on-Tangible-Asset

Bright Minds Biosciences (XCNQ:DRUG) Return-on-Tangible-Asset : -97.86% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bright Minds Biosciences's annualized Net Income for the quarter that ended in Dec. 2023 was C$-6.74 Mil. Bright Minds Biosciences's average total tangible assets for the quarter that ended in Dec. 2023 was C$6.88 Mil. Therefore, Bright Minds Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -97.86%.

The historical rank and industry rank for Bright Minds Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

XCNQ:DRUG' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -93.17   Med: -80.23   Max: -54.67
Current: -76.78

During the past 4 years, Bright Minds Biosciences's highest Return-on-Tangible-Asset was -54.67%. The lowest was -93.17%. And the median was -80.23%.

XCNQ:DRUG's Return-on-Tangible-Asset is ranked worse than
72.81% of 1556 companies
in the Biotechnology industry
Industry Median: -40.005 vs XCNQ:DRUG: -76.78

Bright Minds Biosciences Return-on-Tangible-Asset Historical Data

The historical data trend for Bright Minds Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Return-on-Tangible-Asset Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Return-on-Tangible-Asset
-54.67 -82.72 -93.17 -77.74

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.03 -76.15 -63.23 -79.69 -97.86

Competitive Comparison of Bright Minds Biosciences's Return-on-Tangible-Asset

For the Biotechnology subindustry, Bright Minds Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Return-on-Tangible-Asset falls into.



Bright Minds Biosciences Return-on-Tangible-Asset Calculation

Bright Minds Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=-7.372/( (12.087+6.879)/ 2 )
=-7.372/9.483
=-77.74 %

Bright Minds Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-6.736/( (6.879+6.887)/ 2 )
=-6.736/6.883
=-97.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Bright Minds Biosciences  (XCNQ:DRUG) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Bright Minds Biosciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences (XCNQ:DRUG) Headlines

From GuruFocus

Bright Minds Biosciences Announces Resignation of Board Member

By Stock market mentor Stock market mentor 01-09-2023